MELISSA Mobile Artificial Intelligence Solution for Diabetes Adaptive Care
- Coordinator
- Universiteit Maastricht, Netherlands
- Runs
- 1 June 2022 to 31 May 2027
- Status
- Running
- EU funding
- €6.0m
- Total cost
- €6.1m
- Partners
- 12 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057730
What the project is doing
In the project's own words, from its summary on CORDIS.
The MELISSA project aims to provide a clinically validated, effective, trustworthy, and cost-efficient artificial intelligence (AI)-based digital diabetes management solution to support both health care providers (HCPs) and insulin-treated patients with diabetes (PwD) in their daily routine with personalised treatment and care recommendations. The solution is independent of the used glucose monitoring devices and is based on the combined use of already prototyped advanced AI-approaches and innovative tools for quantification of lifestyle and behavioural factors, taking into consideration sex/gender aspects, age, and socio-economic parameters related to the development of diabetes.
More specifically, core element of the project is the daily insulin treatment adjustment to ensure glucose control using an already introduced self-learning approach based on reinforcement learning. The approach is data-driven, real-time and of low computational cost and allows daily adjustment of the insulin infusion profile, on the basis of the fluctuations in the patient?s glucose. The approach takes into consideration patients treatment-related (glucose, insulin, and carbohydrate intake) and conceptual information and during the project will be further extended and optimized to include additional lifestyle and behavioural parameters.
Furthermore, tools for assessing the risk of short- and long-term complications will assist HCPs in reaching better decisions on adjustments to the treatment schemes. To meet the objectives the consortium brings together partners active in the fields of diabetes (PwD and HCPs), diabetes technology, AI, behavioral sciences, ethics in AI, regulatory affairs, healthcare economics and clinical trials to further co-create, clinically develop, optimize, and clinically validate an AI-based solution for more effective and cost-efficient diabetes management through personalised treatment and care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Maastricht | Maastricht | Netherlands | Coordinator |
| Debiotech S.a. | Lausanne | Switzerland | Associatedpartner |
| Universitaet Bern | Bern | Switzerland | Associatedpartner |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Otto-Von-Guericke-Universitaet Magdeburg | Magdeburg | Germany | Participant |
| Profil Institut Fur Stoffwechselforschung GmbH | Neuss | Germany | Participant |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Geniko Nosokomeio Paidon Athinon Panagiotoy Kai Aglaias Kyriakoy | Athina | Greece | Participant |
| Universidad De Navarra | Pamplona | Spain | Participant |
| Breakthrough T1d | New York | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI